MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
INmune Bio ROCE Ratio 2011-2026 | INMB
Annual ROCE Ratio INmune Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -201.42 | -132.83 | -79.65 | -43.18 | -36.34 | -31.45 | -39.12 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -31.45 | -201.42 | -80.57 |
Quarterly ROCE Ratio INmune Bio
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -182.03 | -124.11 | -97.99 | -117.4 | -105.05 | -90.51 | -43.68 | -55.37 | -47.64 | -44.12 | -29.38 | -39.6 | -38.14 | -44.17 | -32.54 | -44.97 | -47.19 | -37.47 | -23.27 | -36.34 | -36.96 | -33.34 | -22.97 | -32.28 | -28.53 | -64.04 | -63.85 | -63.85 | -54.54 | -17.21 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -17.21 | -182.03 | -56.62 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.85 | 3.22 % | $ 9.26 B |  Australia |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 326.45 | -2.08 % | $ 42.8 B | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 4.71 | -0.42 % | $ 766 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.49 | 2.65 % | $ 351 M | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 8.14 | 9.7 % | $ 80.5 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.85 | 0.78 % | $ 1.02 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 101.25 | 1.78 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.15 | -0.63 % | $ 5.19 M | Israel |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 2.3 | -10.16 % | $ 147 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.4 | -10.0 % | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.22 | -0.5 % | $ 451 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.98 | -2.44 % | $ 3.05 B | USA |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 8.58 | -1.29 % | $ 6.83 B |  Spain |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.53 | 2.35 % | $ 407 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-75.78 | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
156.13 | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 33.75 | -0.35 % | $ 2.24 B | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |